Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer

Paolo Pronzato, Marco Landuccia, Franco Vairaa, Antonella Vigania, Gianfdippo Bertelli

Research output: Contribution to journalArticle

Abstract

Twenty-four outpatients with locally advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were treated with carboplatin (300 mg/m2 day 1) + etoposide (120 mg/2 day 1-3), every 3 weeks. Two patients died of disease progression before completing at least 2 cycles of chemotherapy. Four patients (16.7%) obtained a partial response, 10 had disease stabilization (41.7%) and 8 progressed (33.3%). Median overall survival was 8 months (range 1-22). Toxicity was moderate, with no nephro-, neuro- or ototoxicity

Original languageEnglish
Pages (from-to)144-148
Number of pages5
JournalChemotherapy
Volume40
Issue number2
DOIs
Publication statusPublished - 1994

Keywords

  • Carboplatin
  • Etoposide
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this